Benitec Biopharma (BNTC) Receivables (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Receivables for 7 consecutive years, with $3000.0 as the latest value for Q1 2025.
- Quarterly Receivables fell 94.34% to $3000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Mar 2025, down 94.34% year-over-year, with the annual reading at $229000.0 for FY2024, 316.36% up from the prior year.
- Receivables hit $3000.0 in Q1 2025 for Benitec Biopharma, up from $2000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $229000.0 in Q2 2024 to a low of $2000.0 in Q4 2024.
- Historically, Receivables has averaged $37058.8 across 5 years, with a median of $10000.0 in 2021.
- Biggest five-year swings in Receivables: skyrocketed 1733.33% in 2023 and later plummeted 96.23% in 2024.
- Year by year, Receivables stood at $5000.0 in 2021, then surged by 1260.0% to $68000.0 in 2022, then fell by 22.06% to $53000.0 in 2023, then tumbled by 96.23% to $2000.0 in 2024, then skyrocketed by 50.0% to $3000.0 in 2025.
- Business Quant data shows Receivables for BNTC at $3000.0 in Q1 2025, $2000.0 in Q4 2024, and $4000.0 in Q3 2024.